Biotie Therapies

From Wikipedia, the free encyclopedia

Biotie Therapies (OMX: BTH1V) is a Finnish biotechnology and pharmaceutics company. The company's research and development is focused on dependence disorders, inflammatory diseases and thrombosis. The company's headquarter is located in Turku, Western Finland, and it is listed on Helsinki Stock Exchange.

Biotie Therapies was formed in the merger of Biotie Therapies Corp., Oy Contral Pharma Ltd and its subsidiary Carbion Inc in the year 2002. In the year 2006 the company generated revenue of 1,12 million euros.